Michael Happich

2.3k total citations · 1 hit paper
60 papers, 1.7k citations indexed

About

Michael Happich is a scholar working on Economics and Econometrics, General Health Professions and Psychiatry and Mental health. According to data from OpenAlex, Michael Happich has authored 60 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Economics and Econometrics, 15 papers in General Health Professions and 15 papers in Psychiatry and Mental health. Recurrent topics in Michael Happich's work include Health Systems, Economic Evaluations, Quality of Life (29 papers), Dementia and Cognitive Impairment Research (10 papers) and Musculoskeletal pain and rehabilitation (7 papers). Michael Happich is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (29 papers), Dementia and Cognitive Impairment Research (10 papers) and Musculoskeletal pain and rehabilitation (7 papers). Michael Happich collaborates with scholars based in Germany, United States and United Kingdom. Michael Happich's co-authors include Rolf Holle, H.-Erich Wichmann, Hannelore Löwel, Catherine Reed, Diego Novick, Jihyung Hong, Mark Belger, Lusine Breitscheidel, Giuseppe Bruno and Josep María Haro and has published in prestigious journals such as Spine, Clinical Pharmacology & Therapeutics and BMC Medical Research Methodology.

In The Last Decade

Michael Happich

58 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KORA - A Research Platform for Population Based Health Research

2005 508 citations Rolf Holle, Michael Happich et al. Das Gesundheitswesen profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Happich Germany	21	380	355	299	281	269	60	1.7k
Rod Walker United States	26	543 1.4×	207 0.6×	114 0.4×	225 0.8×	519 1.9×	90	2.9k
Mariëlle H. Emmelot‐Vonk Netherlands	25	251 0.7×	226 0.6×	121 0.4×	223 0.8×	542 2.0×	94	2.4k
Patrick G. O’Malley United States	31	543 1.4×	168 0.5×	289 1.0×	275 1.0×	308 1.1×	81	3.4k
Jack M. Guralnik United States	12	281 0.7×	139 0.4×	121 0.4×	137 0.5×	661 2.5×	12	1.9k
Janet M. Grubber United States	24	202 0.5×	110 0.3×	355 1.2×	119 0.4×	276 1.0×	64	2.4k
Estella Musacchio Italy	27	179 0.5×	157 0.4×	96 0.3×	131 0.5×	578 2.1×	56	2.0k
Jessica E. Lockery Australia	22	230 0.6×	99 0.3×	113 0.4×	141 0.5×	151 0.6×	47	1.3k
Janne Martikainen Finland	22	393 1.0×	349 1.0×	253 0.8×	47 0.2×	149 0.6×	104	1.4k
Shlomo Noy Israel	23	602 1.6×	104 0.3×	205 0.7×	114 0.4×	208 0.8×	66	1.7k
C J Bulpitt United Kingdom	29	200 0.5×	171 0.5×	160 0.5×	138 0.5×	207 0.8×	97	2.8k

Countries citing papers authored by Michael Happich

Since Specialization

Citations

This map shows the geographic impact of Michael Happich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Happich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Happich more than expected).

Fields of papers citing papers by Michael Happich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Happich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Happich. The network helps show where Michael Happich may publish in the future.

Co-authorship network of co-authors of Michael Happich

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Happich. A scholar is included among the top collaborators of Michael Happich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Happich. Michael Happich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mühlbacher, Axel, F. Reed Johnson, Jui‐Chen Yang, Michael Happich, & Mark Belger. (2016). Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer’s Disease. Value in Health. 19(1). 66–74. 20 indexed citations

Hornberger, John, et al.. (2015). Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.. PubMed. 18(2). 63–73. 15 indexed citations

Schacht, Alexander, et al.. (2014). Impact of Pretreatment With Antidepressants on the Efficacy of Duloxetine in Terms of Mood Symptoms and Functioning. The Primary Care Companion For CNS Disorders. 16(5). 2 indexed citations

Chen, Lei, Catherine Reed, Michael Happich, Allen W. Nyhuis, & Alan Lenox‐Smith. (2014). Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer’s disease: a retrospective, matched case–control study in the United Kingdom. BMC Geriatrics. 14(1). 76–76. 38 indexed citations

Wielage, Ronald C., Megha Bansal, J. Scott Andrews, Robert W. Klein, & Michael Happich. (2013). Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective. Applied Health Economics and Health Policy. 11(3). 219–236. 19 indexed citations

Wielage, Ronald C., et al.. (2013). Cost Effectiveness of Duloxetine for Osteoarthritis: A Quebec Societal Perspective. Arthritis Care & Research. 66(5). 702–708. 7 indexed citations

Wielage, Ronald C., et al.. (2013). Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review. Applied Health Economics and Health Policy. 11(6). 593–618. 18 indexed citations

Wimo, Anders, Catherine Reed, Richard Dodel, et al.. (2013). The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries – Study Design and Baseline Findings. Journal of Alzheimer s Disease. 36(2). 385–399. 127 indexed citations

Shi, Nianwen, et al.. (2012). Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom. Journal of Medical Economics. 15(4). 672–680. 3 indexed citations

10.

Wielage, Ronald C., et al.. (2012). PRM145 A Maximum Likelihood Simulation Technique for Estimating Adverse Event Rates From Published Trials. Value in Health. 15(7). A487–A487. 3 indexed citations

11.

Lengerke, Thomas von, et al.. (2010). Excess Health Care Costs of Obesity in Adults with Diabetes Mellitus: a Claims Data Analysis. Experimental and Clinical Endocrinology & Diabetes. 118(8). 496–504. 15 indexed citations

12.

Mittendorf, Thomas, et al.. (2009). Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost‐effectiveness analysis in the German setting. Diabetes Obesity and Metabolism. 11(11). 1068–1079. 29 indexed citations

13.

Meisinger, Christa, Margit Heier, Rüdiger Landgraf, et al.. (2008). Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study. BMC Health Services Research. 8(1). 226–226. 20 indexed citations

14.

Happich, Michael, et al.. (2008). The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002—Results from the diabetic microvascular complications (DIMICO) study. Diabetes Research and Clinical Practice. 81(2). 223–230. 55 indexed citations

15.

Schöffski, Oliver, et al.. (2008). Die gesamtgesellschaftliche Belastung durch die hyperkinetische Störung (HKS) bzw. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). Das Gesundheitswesen. 70(7). 398–403. 12 indexed citations

16.

Davidov, Eldad, et al.. (2008). Diabetic retinopathy and health-related quality of life. Graefe s Archive for Clinical and Experimental Ophthalmology. 247(2). 267–272. 52 indexed citations

17.

Buchner, Florian, et al.. (2007). Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set. The European Journal of Health Economics. 8(1). 31–39. 14 indexed citations

18.

Happich, Michael, U Reitberger, Lusine Breitscheidel, Michael Ulbig, & Jessamy Watkins. (2007). The economic burden of diabetic retinopathy in Germany in 2002. Graefe s Archive for Clinical and Experimental Ophthalmology. 246(1). 151–159. 49 indexed citations

19.

Teipel, Stefan, et al.. (2007). Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease. European Archives of Psychiatry and Clinical Neuroscience. 257(6). 330–336. 26 indexed citations

20.

Buchner, Florian, et al.. (2004). Risk-Adjusted Capitation Payments: How Well Do Principal Inpatient Diagnosis-Based Models Work in the German Situation? Results From a Large Data Set. RePEc: Research Papers in Economics. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact